4-{4-[2-chloro-5-(trifluoromethyl)benzenesulfonyl]piperazin-1-yl}-4-oxobut-2-enoic acid

Catalog No. :
ACUXWI921
CAS No. :
743445-12-7
Molecular Formula :
C15H14ClF3N2O5S
Molecular Weight :
426.80

IUPAC Name:(E)-4-(4-((2-chloro-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-1-yl)-4-oxobut-2-enoic acid

4-{4-[2-chloro-5-(trifluoromethyl)benzenesulfonyl]piperazin-1-yl}-4-oxobut-2-enoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$100.00Login to see priceInquiryInquiry
250mg95%$195.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-{4-[2-chloro-5-(trifluoromethyl)benzenesulfonyl]piperazin-1-yl}-4-oxobut-2-enoic acid
IUPAC Name(E)-4-(4-((2-chloro-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-1-yl)-4-oxobut-2-enoic acid
MDL No.MFCD05263276
Molecular FormulaC15H14ClF3N2O5S
Molecular Weight426.80
SMILESO=C(O)/C=C/C(N1CCN(S(=O)(C2=CC(C(F)(F)F)=CC=C2Cl)=O)CC1)=O
InChI KeyWHADDUZFGJTOFT-ONEGZZNKSA-N
Synonym2-Butenoic acid, 4-[4-[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl]-4-oxo-;4-(4-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)-4-oxobut-2-enoic acid
CAS No.743445-12-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACUXWI921 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUXWI921 route product structure diagram
    ACUXWI921743445-12-7
Inquiry

2. ACUXWI921 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUXWI921 route product structure diagram
    ACUXWI921743445-12-7
Inquiry

Comments (0)